何玲玲;王海琳;

• 1:兰州大学第一临床医学院
• 2:甘肃省人民医院

摘要(Abstract)：

卵巢癌是致命的妇科恶性肿瘤,通常起病隐匿,初治时多为晚期,即使给予手术和系统化疗获得临床缓解后,仍有75%的患者复发,治疗方法的选择是临床工作中的难题。复发性卵巢癌的治疗方法包括手术疗法、化学疗法、靶向疗法、免疫疗法、放射疗法,临床医师应针对患者类型选择合适的治疗方式。

关键词(KeyWords)： 卵巢癌;复发性卵巢癌;手术疗法;化学疗法;靶向疗法;免疫疗法;放射疗法

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 何玲玲;王海琳;

Email:

DOI:

参考文献(References)：

• [1] TORRE L A,TRABERT B,DESANTIS C E,et al.Ovarian cancer statistics,2018[J].CA Cancer J Clin,2018,68(4):284-296.
• [2] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
• [3] MARCHETTI C,ROSATI A,SCALETTA G,et al.Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance:still getting any benefit A case-control study[J].Gynecol Oncol,2019,155(3):400-405.
• [4] COLEMAN R L,SPIRTOS N M,ENSERRO D,et al.Secondary surgical cytoreduction for recurrent ovarian cancer[J].N Engl J Med,2019,381(20):1929-1939.
• [5] 卢淮武,霍楚莹,许妙纯,等.《2020 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2020,36(4):340-348.
• [6] SAMARTZIS K,THOMAKOS N,LIONTOS M,et al.Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management a reappraisal[J].J Buon,2018,23(7):19-23.
• [7] FAGOTTI A,COSTANTINI B,PETRILLO M,et al.Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients:a case-control study on survival in patients with two year follow-up[J].Gynecol Oncol,2012,127(3):502-505.
• [8] ARJONA-SANCHEZ A,RUFIAN-PENA S.Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre[J].Int J Hyperthermia,2017,33(5):554-561.
• [9] CORTEZ A J,TUDREJ P,KUJAWA K A,et al.Advances in ovarian cancer therapy[J].Cancer Chemother Pharmacol,2018,81(1):17-38.
• [10] PARMAR M K,LEDERMANN J A,COLOMBO N,et al.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial[J].Lancet,2003,361(9375):2099-2106.
• [11] PFISTERER J,PLANTE M,VERGOTE I,et al.Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR,the NCIC CTG,and the EORTC GCG[J].J Clin Oncol,2006,24(29):4699-4707.
• [12] RAJA F A,COUNSELL N,COLOMBO N,et al.Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer:a meta-analysis using individual patient data[J].Ann Oncol,2013,24(12):3028-3034.
• [13] PUJADE-LAURAINE E,BANERJEE S,PIGNATA S.Management of platinum-resistant,relapsed epithelial ovarian cancer and new drug perspectives [J].J Clin Oncol,2019,37(27):2437-2448.
• [14] PIGNATA S,LORUSSO D,SCAMBIA G,et al.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11):a randomised,open-label,phase 2 trial[J].Lancet Oncol,2015,16(5):561-568.
• [15] TOMAO F,D′INCALCI M,BIAGIOLI E,et al.Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval:Myth or reality[J].Cancer,2017,123(18):3450-3459.
• [16] CHEKEROV R,HILPERT F,MAHNER S,et al.Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS):a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet Oncol,2018,19(9):1247-1258.
• [17] LAN C Y,WANG Y,XIONG Y,et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC):a phase 2,single-arm,prospective study[J].Lancet Oncol,2018,19(9):1239-1246.
• [18] PRAKASH R,ZHANG Y,FENG W R,et al.Homologous recombination and human health:the roles of BRCA1,BRCA2,and associated proteins[J].Cold Spring Harb Perspect Biol,2015,7(4):a016600.
• [19] PENNINGTON K P,WALSH T,HARRELL M I,et al.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian,fallopian tube,and peritoneal carcinomas[J].Clin Cancer Res,2014,20(3):764-775.
• [20] PUJADE-LAURAINE E,LEDERMANN J A,SELLE F,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21):a double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18(9):1274-1284.
• [21] SWISHER E M,LIN K K,OZA A M,et al.Rucaparib in relapsed,platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1):an international,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2017,18(1):75-87.
• [22] COLEMAN R L,OZA A M,LORUSSO D,et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10106):1949-1961.
• [23] MIRZA M R,MONK B J,HERRSTEDT J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].N Engl J Med,2016,375(22):2154-2164.
• [24] GUNDERSON C C,MATULONIS U,MOORE K N.Management of the toxicities of common targeted therapeutics for gynecologic cancers[J].Gynecol Oncol,2018,148(3):591-600.
• [25] CHELARIU-RAICU A,COLEMAN R L,SOOD A K.Anti-angiogenesis therapy in ovarian cancer:which patient is it most likely to benefit[J].Oncology (Williston Park),2019,33(7):629378.
• [26] AGHAJANIAN C,GOFF B,NYCUM L R,et al.Final overall survival and safety analysis of OCEANS,a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer[J].Gynecol Oncol,2015,139(1):10-16.
• [27] LEDERMANN J A,EMBLETON A C,RAJA F,et al.Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6):a randomised,double-blind,placebo-controlled phase 3 trial[J].Lancet,2016,387(10023):1066-1074.
• [28] MONK B J,POVEDA A,VERGOTE I,et al.Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1):Long-term survival,impact of ascites,and progression-free survival-2[J].Gynecol Oncol,2016,143(1):27-34.
• [29] ODUNSI K.Immunotherapy in ovarian cancer[J].Ann Oncol,2017,28(Suppl8):viii1-viii7.
• [30] HAMANISHI J,MANDAI M,IKEDA T,et al.Safety and antitumor activity of anti-PD-1 antibody,nivolumab,in patients with platinum-resistant ovarian cancer[J].J Clin Oncol,2015,33(34):4015-4022.
• [31] 鲁添福,王娇.DC-CIK细胞免疫治疗和化疗对复发性卵巢癌患者血清指标的影响[J].临床医学研究与实践,2018,3(23):70-72.
• [32] JIANG G,BALBONI T,TAYLOR A,et al.Palliative radiation therapy for recurrent ovarian cancer:efficacy and predictors of clinical response[J].Int J Gynecol Cancer,2018,28(1):43-50.